Literature DB >> 10678290

Levalbuterol nebulizer solution: is it worth five times the cost of albuterol?

M J Asmus1, L Hendeles.   

Abstract

Albuterol is a 50:50 mixture of R-albuterol, the active enantiomer, and S-albuterol, which appears to be inactive in humans. The Food and Drug Administration recently approved levalbuterol, the pure R-isomer, as a preservative-free nebulizer solution. Published studies indicate that it is neither safer nor more effective than an equimolar dose of racemic albuterol (levalbuterol 1.25 mg = albuterol 2.5 mg). However, these studies were conducted in patients with stable asthma (at the top of the dose-response curve), whereas a nebulized bronchodilator most likely would be used by patients with an acute exacerbation. Because such patients, in the hospital setting, often require higher doses of albuterol, the manufacturer's recommended dose of levalbuterol is likely to be too low for rescue therapy. Levalbuterol may cost as much as 5 times more than racemic albuterol, depending on purchase method. We conclude that levalbuterol offers no advantage over albuterol but is likely to be more costly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10678290     DOI: 10.1592/phco.20.3.123.34776

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  6 in total

1.  Advocating for patients through clinical research.

Authors:  Leslie Hendeles
Journal:  J Pediatr Pharmacol Ther       Date:  2008-01

Review 2.  The pharmacokinetics of levosalbutamol: what are the clinical implications?

Authors:  D W Boulton; J P Fawcett
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 3.  Common pediatric respiratory emergencies.

Authors:  Joseph Choi; Gary L Lee
Journal:  Emerg Med Clin North Am       Date:  2011-12-17       Impact factor: 2.264

4.  Chiral drugs: an overview.

Authors:  Lien Ai Nguyen; Hua He; Chuong Pham-Huy
Journal:  Int J Biomed Sci       Date:  2006-06

Review 5.  Single-isomer levalbuterol: a review of the acute data.

Authors:  Richard Nowak
Journal:  Curr Allergy Asthma Rep       Date:  2003-03       Impact factor: 4.919

6.  An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation.

Authors:  Xuemei Zhang; Qing Liu; Junhua Hu; Ling Xu; Wen Tan
Journal:  Acta Pharm Sin B       Date:  2014-01-18       Impact factor: 11.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.